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a b s t r a c t
The clinical significance of timely re-epithelialization is obvious in burn care, since
delayedwound closure is enhancing the risk of wound site infection and extensive scarring.
Topical treatments that accelerate wound healing are urgently needed to reduce these
sequelae.Evidence from preliminarystudiessuggests thatbetulin can acceleratethe healing of
different types of wounds, including second degree burns and split-thickness skin graft
wounds.
The goal of this combined study program consisting of two randomized phase III clinical
trials in parallel is to evaluate whether a topical betulin gel (TBG) is accelerating re-
epithelialization of split-thickness skin graft (STSG) donor site wounds compared to standard
of care.
Two parallel blindly evaluated, randomised, controlled, multicentre phase III clinical
trialswere performed in adults undergoing STSG surgery (EudraCT nos. 2012-003390-26 and
2012-000777-23). Donor site wounds were split into two equal halves and randomized 1:1 to
standard of care (a non-adhesive moist wound dressing) or standard of care plus TBG
consisting of 10% birch bark extract and 90% sunflower oil (Episalvan, Birken AG, Niefern-
Oeschelbronn,Germany).Theprimaryefficacyassessment wasthe intra-individualdifference
in time to wound closure assessed from digital photographs by three blinded experts.
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A total of 219 patients were included and treated in the two trials. Wounds closed faster with
TBG than without it (15.3 vs. 16.5 days; mean intra-individual difference=1.1 days [95% CI,
1.5 to 0.7]; p<0.0001).
This agreed with unblinded direct clinical assessment (difference=2.1 days [95% CI, 2.7 to
1.5]; p<0.0001). Adverse events possibly related to treatment were mild or moderate and
mostly at the application site.
TBG accelerates re-epithelialization of partial thickness wounds compared to the current
standard of care, providing a well-tolerated contribution to burn care in practice.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cutaneous wound healing is a complex biological process
leading to re-establishment of the epidermal barrier. The
clinical significance of timely wound closure is obvious in
extensive wounds like burns, when delayed healing can lead to
infection of the wound site and scarring. Topical treatments
that accelerate wound healing are urgently needed to reduce
these sequelae.
Growth factors, stem cells, nanoparticles, platelet-rich
plasma, cold atmospheric pressure physical plasma [1] and
many other topical treatments have been investigated [2–5],
but none have proven effective in clinical trials and no
treatment or pharmaceutical is currently available to
accelerate the secondary closure of open superficial surgical
sites or other partial-thickness wounds. Therefore, the
current standard of care for open superficial surgical sites
remains a moisture-regulating dressing, which promotes re-
epithelialization by preventing desiccation [6,7].
Betulin is a pentacyclic triterpene found in the outer bark of
white barked birches (Betula) [8]. Betulin has been reported to
promote healing in a porcine ex vivo wound healing model and
to modulate inflammatory mediators and promote keratino-
cyte differentiation and migration in vitro [9,10]. Evidence from
preliminary studies suggests that betulin can improve the
healing of different types of skin lesions, including second-
degree burns [11] and necrotizing herpes [12]. A proof-of-
concept phase II clinical study showed that topical betulin gel
(TBG) consisting of 10% birch bark extract and 90% sunflower
oil (Episalvan, Birken AG, Niefern-Oeschelbronn, Germany)
significantly accelerates re-epithelialization of split-thickness
skin graft (STSG) donor sites [13]. This water-free oleogel is
thixotropic: when agitated TBG becomes less viscous making it
easy to spread, and at rest it thickens again providing a stable
occlusive cover [14,15]. Herein, we describe the results of a
study program consisting of two related phase III clinical trials
including a total of more than 200 patients confirming the
clinical effectiveness and safety of TBG in healing of STSG
donor site wounds.
2. Methods
2.1. Study design
The program design is consisting of two open, blindly
evaluated, prospective, controlled, randomised, multi-centre
phase III clinical trials, both using the same protocol. Study
BSG-12 (EudraCT no. 2012-003390-26) was performed in Spain
(6 centres), Greece (3 centres), Latvia (2 centres), and France
(3 centres), and study BSH-12 (EudraCT no. 2012-000777-23)
was performed in Germany (8 centres), Czech Republic
(2 centres), Poland (1 centre), Finland (1 centre), Austria
(2 centres), and Bulgaria (4 centres). The principal objective
of the study was to examine the efficacy and tolerability of
TBG. The primary efficacy endpoint was the intra-individual
difference in time to wound closure (95% epithelialization)
between two equal halves of STSG donor site wounds treated
with either a standard moist wound dressing alone or a
standard moist wound dressing containing TBG. The assess-
ment was based on photo evaluation by a remote panel of three
blinded experts. Study protocols were approved by the local or
regional ethics committee for each centre (for the leading
study centres: Ethic Committee of the Greifswald University
Medicine, Greifswald, Germany and Ethic Committee of Vall
d’Hebron University Hospital, Barcelona, Spain) and the
studies were performed in compliance with International
Conference on Harmonisation guidelines for Good Clinical
Practice and the principles in the Declaration of Helsinki. All
investigators and study team members received training in the
study protocol and in the standardized acquisition of photo-
graphs. Informed consent was obtained from patients before
inclusion in each study.
2.2. Patients
Adults with STSG donor site wounds 15cm2 and 3cm wide
were considered for enrolment. As a routine safety measure all
study participants had to be using a highly effective method of
birth control. Exclusions included skin disorders that could
affect the outcome of the trial; clinically significant hypersen-
sitivity to any of the treatments used in the trial; multiple
allergic disorders; or other diseases or conditions that could
interfere with the study assessments. Women could not be
pregnant or breastfeeding.
2.3. Interventions
Prior to STSG surgery, the donor site was divided into two equal
halves. After STSG harvest and marking of the wound halves,
an overview photo was taken with a digital camera using the
same standard settings at all participating centres. Once the
overview photo was uploaded, the two wound halves were
randomised 1:1 to TBG (other names: Oleogel-S10, Episalvan)
combined with a non-adhesive moist wound dressing as
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Fig. 1 – Marking, blinding, and reading of wound halves.
Original photo series taken on days 0 (a), 2 (not shown), 5 (b), 8 (c) and 15 (d). Immediately after split-thickness skin harvest, the
donor site wound was divided in two halves, marked ‘Pr’ for proximal and ‘Di’ for distal (a). Randomisation then assigned
treatments to the wound halves. Skin next to the wound half to be treated with topical betulin gel was marked as ‘Ver’ (verum)
and skin next to the control wound half was marked as ‘-’ (b–d).Prior to the blinded read, markings were cropped from the photo
and checked by a medical expert. Only photos that were confirmed to be free of markings or other details that could have
compromised blinding (e.g., gel residue) were considered for a blinded read. Eligible photographs were divided into two halves
based on the skin markings, then photo series of separate wound halves were evaluated by three wound experts via a web-
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standard of care or the wound dressing alone. Dressings were
trimmed to the appropriate size for the wound and then cut in
half, and after cleaning, TBG was applied approximately 1mm
thick to the appropriate wound half on the wound-facing side
of the dressing or directly onto the wound (Fig. 1). Every 3 or
4 days according to protocol or more frequently if medically
necessary, the wound dressing was changed, the wound was
cleaned, and medication was applied for the appropriate
wound half. Treatment continued up to complete closure of
both halves of the wound or, if complete closure of both wound
halves was not observed, until day 28.
2.4. Assessments
For observer-blinded analysis of wound closure, at each
wound dressing change and after cleaning the wound, photos
were taken with a Nikon Coolpix P510 camera with fixed
settings at all participating centres. For evaluation of long-time
outcome, photos were taken 3 and 12 months after treatment.
For the unblinded analysis, investigators estimated the degree
of epithelialization (% of the original wound half size) for each
wound half.
Investigators collected adverse events (AEs) in accordance
with International Committee for Harmonisation guidelines
for Good Clinical Practice. AEs were encoded using MedDRA
version 16.0 (MedDRA MSSO, McLean, VA, USA). Causality as
unrelated or as unknown, unlikely, possibly, or probably
related to the treatment. AE severity was graded according to
the National Cancer Institute Common Toxicity Criteria for
Adverse Events version 4.0.
At days 7, 14, and 21 and at the end of treatment, patients
and investigators answered questionnaires about the efficacy
and tolerability of the two treatments on a 5-point Likert scale
(which treatment was more effective/which treatment was
better tolerated) [16,17].
2.5. Randomisation and masking
Randomisation was via an interactive web response system.
For photo evaluations, observers were blinded by using a web-
based electronic blinded read tool.
2.6. Analysis of photos
Markings were cropped from the photo, and photos were
checked by investigators not involved in safety or efficacy
assessments (Fig. 1). Only photos confirmed to be free of
markings were considered for a blinded read of efficacy and
tolerability. Eligible photographs were independently eval-
uated by three wound experts (experienced surgeons or
dermatologists) via a web-based electronic blinded read
tool. All available photos from one wound half comprising a
photo series were presented to each blinded expert without
information about the treatment, and the order of series
was randomised. Within each series, photos were pre-
sented in chronological order but with no information on
the specific treatment day at which each photo was taken.
For photo series that the reader considered evaluable,
readers assessed which series was the first to show wound
closure (epithelialization of 95% of the wound half) or
whether wound closure could not be detected in any of the
photos. When wound closure was not observed, it was
assumed to have closed 1 day after the last observation.
Long-term outcomes were estimated using the same
method and included determination of which wound half
was most similar to surrounding healthy tissue in terms of
texture, hair growth, pigmentation, and redness.
2.7. Sample size
Each study planned to enrol 105 subjects to reach a total of
more than 200 patients for the TBG safety database. This was
estimated to allow detection of a primary outcome (mean
intra-individual difference in time to wound closure) of
1.9 days in each study at an alpha of 0.05 and 90% power,
given a standard deviation of 6.0 days.
2.8. Statistical analysis
Statistical analysis was performed using SAS version 9.3 (Cary,
NC). A p-value below 0.05 was considered statistically
significant. Efficacy was initially analysed within the intent-
to-treat analysis set, which included all patients who signed
informed consent and who were treated at least once with
TBG. The primary endpoint (intra-individual difference in time
to wound closure) was calculated from the means of the values
for each of the three blinded experts. Median time to wound
closure was used for Kaplan–Meier analysis. If more than one
expert considered a photo series as not evaluable, the
corresponding wound half was not included in the analysis.
The percentage of patients with wound closure over time was
determined using a last observation carried forward approach.
The percentage of wound epithelialization as assessed by
investigators during dressing change was compared at each
time point by a paired t-test and a non-parametric sign test.
Baseline characteristics and safety were analysed within the
safety analysis set, which included all patients who received at
least one treatment.
3. Results
3.1. Patients and studies
Study BSG-12 was conducted between April 5 and September
25, 2013 and enrolled 113 adult patients of whom 112 were
treated. Study BSH-12 was performed between August 3,
2012 and August 23, 2013 and enrolled 111 adult patients of
whom 107 were treated. The patients were on average
52.6 years of age (Table 1). Nearly two-thirds (64.1%) were
men. Overall, just over half of the patients (54.4%) had
Fitzpatrick skin type I or II, although this was much more
based electronic blinded read tool (e). Readers could magnify areas of interest using a zoom tool (e). The blinded readers
assessed which of the photos in the series was the first to show full wound closure, as defined by 95% epithelialization.
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common in study BSH-12 (79.4%) than in study BSG-12 (30.0%),
consistent with the different regions in which the studies were
performed. Wounds were on average 81.566.4cm2. Mepilex
(Mölnlycke Health Care, Goteborg, Sweden), a siliconized foam
dressing, was selected for most (78%) patients as the standard-
of-care control. For other patients, Allevyn Gentle or Allevyn
Non-Adhesive (Smith & Nephew, Hull, United Kingdom) was
used as the standard-of-care control.
Of the 219 patients who were treated, 174 (79.5%) completed
the treatment period and achieved full wound closure by day
28 or before (Fig. 2). Seventeen patients (7.8%) discontinued
early, 6 (2.7%) of whom discontinued because of AEs. The
remaining 28 (12.8%) patients did not have full wound closure
on both halves.
3.2. Time to wound closure
For about one-third of the patients (35.0%), wound closure was
observed for both halves, and for another one-third (31.8%), full
wound closure was not observed for either half (Table 2). More
of the remaining patients had full wound closure with TBG
+wound dressing (22.6%) than with the wound dressing alone
(3.2%). For a few patients (7.4%), results differed between the
three blinded experts, so whether closure occurred could not
be established.
For the primary analysis, when wound closure was not
observed, it was assumed to have closed 1 day after the last
observation. Using this conservative assessment, wound
closure was faster with TBG+wound dressing than with the
wound dressing alone (15.3 vs. 16.5 days; mean intra-
individual difference=1.1 days [p<0.0001]) (Fig. 3). In addi-
tion, more patients had earlier closure of the wound half
treated with TBG+wound dressing than had earlier closure of
the wound half treated with wound dressing alone (73.9% vs.
26.1% of the 157 patients with a difference in time to wound
closure). Faster wound closure with TBG was also found in
each of the two studies, although the difference was larger for
study BSH-12 (mean, 15.5 vs. 17.1; difference=1.4 days
[p<0.0001]) than for study BSG-12 (mean, 15.1 vs. 16.0 days;
difference=0.8 days [p=0.0232]). Results were also similar
when the analysis was repeated using different analysis sets
(e.g. all patients completing the study and patients completing
according to protocol), as well as for each of the three blinded
experts independently and according to country or centre
(data not shown). Using a less conservative analysis, in which
the mean time passed between the last observation and the
day of wound closure (3.1 days) was used for cases where
wound closure was not observed, the mean intra-individual
difference in time to wound closure was 1.5 days (p<0.0001).
Applying this analysis to a second blinded read of all photos
(i.e., without removal of photos with ointment residue)
resulted in a difference of 2.2 days (p<0.0001). Finally, in
unblinded assessments, investigators reported wound closure
to be 2.1 days faster for areas treated with TBG+wound
dressing than for areas treated with the wound dressing alone
(p<0.0001).
3.3. Safety
During both the treatment and follow-up periods in the two
studies, AEs were reported by 86 (39.3%) patients (thereof
reported by 78 patients within the treatment period), although
only 17 (7.8%) patients had AEs that the investigator considered
related or possibly related to the treatment, all of which were
rated as mild or moderate severity (Table 3). The most common
related or possibly related AEs were skin pain, pruritus, post-
procedural complication, wound complication, and pain.
Thirty-nine patients (17.8%) had AEs at the application site
(Tables 3 and 4). One patient (0.5%) had pruritus and one
patient (0.5%) a skin infection limited to the TBG-treated
wound half. Thirteen patients (5.9%) had application-site AEs
limited to the standard of care-treated wound half, the most
common of which was skin infection (four cases) and two cases
each of skin pain and wound haemorrhage. In 27 (12.3%)
patients, the AE occurred on both wound halves, the most
common of which were infections (five patients with skin
infections, four with wound infections).
SAEs included wound infection in two patients and
bacteraemia, sepsis, post-operative wound complication,
mania, bronchospasm, and diabetic foot, each in one patient.
Both cases of serious wound infection, the severe post-
procedural complication, and the case of mania resulted in
early discontinuation of the study. None of these SAEs were
considered related or possibly related to treatment.
Administration of TBG to STSG donor site wounds did not
lead to plasma levels of betulin higher than natural back-
ground levels (data not shown).
3.4. Patient and investigator assessment of efficacy and
tolerability
In most cases, investigators (60.2%) and patients (56.8%)
considered TBG+wound dressing more or much more effec-
tive than wound dressing alone (Table 5). Only 6.7% of
investigators and 6.3% of patients considered wound dressings
alone to be more effective than wound dressings+TBG. Also,
for almost half of all cases, investigators (44.8%) and patients
(46.1%) considered TBG+wound dressing to be better tolerated
than wound dressing alone, whereas only 1.9% of investigators
and 3.9% of patients considered wound dressing alone to be
better tolerated.
3.5. Long-term outcome
At 3 and 12 months after treatment, wound halves treated with
TBG+dressing were more often similar to the surrounding skin
Table 1 – Baseline characteristics.
Characteristic BSH-12 BSG-12 Pooled
(N=107) (N=110) (N=217)
Age (y), meanSD 54.018.1 51.217.3 52.617.7
Sex, n (%)
Male 68 (63.6) 71 (64.5) 139 (64.1)
Female 39 (36.4) 39 (35.5) 78 (35.9)
Fitzpatrick skin type
I-II 85 (79.4) 33 (30.0) 118 (54.4)
III-V 22 (20.6) 77 (70.0) 99 (45.6)
Wound size (cm2), meanSD 76.474.4 86.557.4 81.566.4
Abbreviation: SD, standard deviation.
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than would halves treated with the dressing alone in terms of
texture (27.5% vs. 7.1% at 3 months [p<0.001], 13.5% vs. 2.7% at
12 months [p=0.002]), redness (28.0% vs. 10.4% [p<0.001] at
3 months, 12.8% vs. 4.1% at 12 months [p=0.015]), and
especially pigmentation (36.8% vs. 10.4% at 3 months
[p<0.001], 23.6% vs. 8.9% at 12 months [p=0.002]) (Table 6).
Hair growth was not affected by TBG (98.4% at 3 months, 98.0%
at 12 months equal for both wound halves).
N=111
N=107
N=97
Study BSH-12
Enrolled
Treated
Complete d treatment
N=82
Complete d treatment
and achi eved  full
wound  clo sure
Both halves  not  full y closed  N=1 0
Oleogel- S10 hal f clo sed  onl y N=4
Standa rd of care  hal f closed  onl y N=1
N=113
N=112
N=105
Study BSG-12
N=92
Both halves  not  full y closed  N= 4
Oleogel- S10 half clo sed  only N=5
Standard of care  half closed  onl y N=4
AE or  other  safet y event  N=1
Did not  adhere  to  protocol  N=4
Withdre w consen t N=4
Lost to follo w-up  N=1
AE or  other  safet y event  N=5
Other N=2 
Fig. 2 – Flow diagram/disposition.
Two studies (BSG-12 and BSH-12) were performed with the same protocol. In study BSH-12, 111 patients were enrolled, and
107 were intra-individually randomized for the wound-half to be treated with TBG and treated. All 107 patients were included in
the analysis (safety analysis set and intent-to-treat analysis set). In study BSG-12, 113 patients were enrolled, and 112 were
intra-individually randomized for the wound-half to be treated with TBG and treated. All 112 patients were included in the
safety analysis set, 2 patients were excluded from the intent-to-treat analysis set related to informed consent documentation.
Of the total of 219 patients who were treated in the two studies, 219 were analysed in the safety analysis set and 217 in the
intent-to-treat analysis set. 174 patients completed the treatment and achieved full wound closure for both wound halves on or
before day 28.
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Fig. 3 – Time to first observation of wound closure.
For each patient, time to wound closure was determined from the median time to wound closure from the three blinded experts.
For each of the three expert readers, the day of closure was the day on which the first photograph in the photo series showed full
wound closure, as defined by 95% epithelialization. Results are for the intent-to-treat analysis set (N=217).
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4. Discussion
The physical, chemical, and pharmacological characteristics
of oleogel-forming triterpenes, especially betulin, were de-
scribed in 2006 [18]. Betulin has since been reported to promote
healing in vivo and in vitro[9,10]. In a previous phase II study in
which 24 Caucasian STSG patients were treated for 14 days
with TBG plus a non-adhesive wound dressing or the wound
dressing alone, re-epithelialization was more often rated as
faster for the TBG-treated half than for the control half (83.3%
vs. 8.3%; p<0.0001) [13].
The two open-label phase III clinical trials described here
extend these findings and confirm that STSG donor sites heal
significantly faster when TBG is added to the current standard
of care, moist dressings lacking pharmacological, antimicro-
bial, or other agents. Efficacy was assessed in these two trials
using a blinded, remote photographic analysis, which corre-
lates well with direct clinical assessment by investigators
[19,20] and is feasible for clinical studies. For the primary
analysis, we used a conservative estimate of time to wound
closure: when wound closure was not observed, the time to
wound closure was assumed to be 1 day after the last
observation, even though at least 2 or 3 days typically passed
between each observation. This meant that the differences in
closure times were underestimated. Indeed, when using the
mean time between visits instead 1 day after the last
observation, the difference increased from 1.1 to 1.5 days.
Both of these calculations underestimate the real difference
because some detail is lost when using photos instead of direct
observation. Using investigators’ direct observations of re-
epithelialization, wound closure was estimated to be approxi-
mately 2 days faster with TBG. Together, the different efficacy
assessments strongly support the conclusion that TBG
Table 2 – Assessment of wound closure.
Measure BSH-12
N=107
BSG-12
N=110
Pooled
N=217
Intra-patient difference in days to wound closurea
Mean (95% CI) 1.4 (1.8, 0.9) 0.8 (1.5, 0.1) 1.1 (1.5, 0.7)
P-value vs. no change <0.0001 0.0232 <0.0001
Days from surgery to wound closurea
TBG, mean (95% CI) 15.5 (14.2, 16.8) 15.1 (14.1, 16.1) 15.3 (14.5, 16.1)
Standard of care, mean (95% CI) 17.1 (15.8, 18.5) 16.0 (14.8, 17.1) 16.5 (15.7, 17.4)
Wound closure, n (%)
For both wound halves 22 (20.6) 52 (47.3) 76 (35.0)
For TBG-treated half only 33 (30.8) 16 (14.5) 49 (22.6)
For standard of care-treated half only 2 (1.9) 5 (4.5) 7 (3.2)
For neither half 43 (40.2) 26 (23.6) 69 (31.8)
Inconclusive 5 (4.7) 11 (10.0) 16 (7.4)
Difference in rate of wound closure, n (%)
No difference between wound halves 33 (30.8) 27 (24.5) 60 (27.6)
Earlier closure for TBG-treated half 66 (61.7) 50 (45.5) 116 (53.5)
Earlier closure for standard of care-treated half 8 (7.5) 33 (30.0) 41 (18.9)
Intra-patient difference in days to wound closure based on
mean time between dressing changesb
2.0 (2.5, 1.4) 1.1 (1.9, 0.3) 1.5 (2.0, 1.1)
P-value vs. no change <0.0001 0.0063 <0.0001
Intra-patient difference in days to wound closure based on mean
time between dressing changesb, secondary blinded read with
all photos presentedc
2.7 (3.4, 2.0) 1.7 (2.6, 0.8) 2.2 (2.8, 1.6)
P-value vs. no change <0.0001 0.0002 <0.0001
Difference in days to wound closure according to investigator
(unblinded) assessment
2.5 (3.3, 1.6) 1.8 (2.6, 1.0) 2.1 (2.7, 1.5)
P-value vs. no change <0.0001 <0.0001 <0.0001
Abbreviations: CI, confidence interval; TBG, topical betulin gel.
a For wound halves for which wound closure was observed in the blinded read, the day of the photo at which wound closure was first observed was
used. For wound halves in which closure was not observed, the wound half was assumed to have closed one day after the last available photograph.
For 5 patients in study BSH-12 and 2 patients in study BSG-12, data for this analysis were missing because photo series were rated as ‘not evaluable’ by
the majority of readers (for other endpoints, intra-patient analyses, these patients were rated as no difference).
b A sensitivity analysis was carried out in which wound halves for which wound closure was not observed were assumed to have healed by the time
of the next dressing change (3–4 days) after the last available photo.
c In the primary blinded read evaluation, a rigorous quality check was implemented to ensure blinding of the observers. As a result, many
photographs were excluded and not presented in the primary blinded read because of apparent gel residue. The secondary blinded read was
conducted with all photographs presented to the blinded observers.
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significantly and substantially accelerated wound healing
compared to this state-of-the-art wound dressing material.
From the clinical point of view there are two important
results of benefit for the patients: The first result is the
reduction of healing time by approximately 2 days, that means
more than 10% less open skin surface period, reduced risk of
contamination with pathogens, and reduced treatment need.
Importantly, TBG was safe and well tolerated, with no serious
adverse events (SAE) or discontinuations considered related to
treatment. Both clinical investigators and patients considered
the tolerability of TBG+the wound dressing to be better than
the wound dressing alone. Only a single patient had AEs
(pruritus and a skin infection) limited to the TBG-treated
wound half. This was the only patient to have early signs of SSI
on the TBG-treated wound half. In contrast, four patients had
early signs of SSI on the wound half treated with the wound
dressing alone. This is likely due to the faster wound healing
with TBG because betulin itself has only modest antimicrobial
activity [21].
The second result is the for many patients even more
important finding of this study, that long-term aesthetic
outcome was better with TBG. In particular, texture, redness,
and pigmentation were better when TBG was applied. Hair
growth, in contrast, was not affected by TBG, which is not
surprising because the surgical removal of the STSG left the
underlying hair follicles intact.
Moist, non-adhesive dressings are the current standard of
care for partial thickness wounds [7,22–25]. Topical treatments
that have been reported to accelerate healing include honey
[26,27] and topical growth factors [28], but the comparator is
generally not the current standard of care, and the studies
have mostly been limited to burn wounds. A few other
treatments (e.g. aloe, MEBO
1
, and RGD peptide) have been
shown to improve healing of burn wounds, but the comparator
Table 3 – Number and percentage of patients with AEs reported during treatment period and follow-up period.
Measure BSH-12 BSG-12 Pooled
(N=107) (N=112) (N=219)
n (%) n (%) n (%)
Any AE 23 (21.5) 63 (56.3) 86 (39.3)
At the application site 12 (11.2) 27 (24.1) 39 (17.8)
Probably or possibly related to treatment 3 (2.8) 14 (12.5) 17 (7.8)
Leading to discontinuation 1 (0.9) 4 (3.6) 5 (2.3)
Probably or possibly related to treatment and leading to discontinuation 0 (0.0) 0 (0.0) 0 (0.0)
Any SAE 6 (5.6) 10 (8.9) 16 (7.3)
Related or possibly related to treatment 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviations: AE, adverse event; SAE, serious adverse event.
Table 4 – Number and percentage of patients with application-site adverse events.
Adverse events BSH-12 (N=107) BSG-12 (N=112) Overall (N=219)
TBG Std of care Generala TBG Std of care Generala TBG Std of care Generala
Impaired healing – – 1 (0.9) – – – – – 1 (0.5)
Skin infection – 2 (1.9) 1 (0.9) 1 (0.9) 2 (1.8) 4 (3.6) 1 (0.5) 4 (1.8) 5 (2.3)
Wound infection – 1 (0.9) 1 (0.9) – – 3 (2.7) – 1 (0.5) 4 (1.8)
Wound haemorrhage – 1 (0.9)b 1 (0.9) – 1 (0.9) 1 (0.9) – 2 (0.9) 2 (0.9)
Skin pain – – 1 (0.9) – 2 (1.8) 4 (3.6) – 2 (0.9) 5 (2.3)
Pruritus – – 1 (0.9) 1 (0.9) – 3 (2.7) 1 (0.5) – 4 (1.8)
Hypersensitivity – – – – – 1 (0.9) – – 1 (0.5)
Post-procedural complication – – – – 1 (0.9) 3 (2.7) – 1 (0.5) 3 (1.4)
Procedural pain – – – – – 2 (1.8) – – 2 (0.9)
Wound complication – – – – – 2 (1.8) – – 2 (0.9)
Wound haematoma – – – – – 2 (1.8) – – 2 (0.9)
Wound secretion – – – – – 1 (0.9) – – 1 (0.5)
Dermatitis – – – – 1 (0.9) – – 1 (0.5) –
Excessive granulation tissue – – – – – 1 (0.9) – – 1 (0.5)
Haematoma – – – – – 1 (0.9) – – 1 (0.5)
Skin ulcer – 1 (0.9)b – – – – – 1 (0.5) –
Keratoacanthoma – 1 (0.9)b – – – – – 1 (0.5) –
Any application site adverse event 0 (0.0) 6 (5.6) 6 (5.6) 2 (1.8) 7 (6.3) 21 (18.8) 2 (0.9) 13 (5.9) 27 (12.3)
Abbreviations: Std, standard; TBG, topical betulin gel.
a Not limited to a single wound half.
b Observed during the follow-up period.
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has usually been silver sulfadiazine, which is now well known
to slow healing [22,29]. Furthermore, study quality has varied
widely, and with the exception of our own previous phase II
study [13], no other phase II or III clinical trials have examined
the ability of topical agents to enhance wound closure or re-
epithelialization.
5. Conclusion
TBG is a safe topical agent that accelerates epidermal barrier
closure of split-thickness skin graft donor sites with faster
secondary re-epithelialization of partial thickness wounds
and reduced scarring, compared to the current standard of
care. TBG is providing a well-tolerated contribution to burn
care in practice.
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Table 6 – Long-term outcome.
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No majority decision or not evaluable 7 (3.8) 4 (2.7)
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Standard of care treated wound half 13 (7.1) 4 (2.7)
Both sides equal 113 (62.1) 124 (83.8)
No majority decision or not evaluable 6 (3.3) 0 (0.0)
Hair growth TBG-treated wound half 2 (1.1) 0.5 2 (1.4) 1.0
Standard of care treated wound half 0 (0.0) 1 (0.7)
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